Enanta Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENTA Nasdaq 2836 www.enanta.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enanta Pharmaceuticals, Inc.

Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates - Aug 5th, 2026 4:10 pm
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Jun 24th, 2026 7:13 am
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates - May 11th, 2026 3:10 pm
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates - May 7th, 2026 3:55 pm
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last? - May 7th, 2026 7:02 am
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference - Mar 15th, 2026 4:41 pm
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock - Feb 12th, 2026 10:00 am
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - Feb 9th, 2026 3:05 pm
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot - Feb 9th, 2026 2:06 pm
JPM26: Enanta outlines strategy to lead in RSV therapeutics - Jan 15th, 2026 3:39 pm
Enanta Pharmaceuticals Insider Ups Holding During Year - Jan 1st, 2026 6:03 am
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? - Dec 26th, 2025 6:42 am
Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains? - Dec 22nd, 2025 7:17 am
Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade - Nov 21st, 2025 7:55 am
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has caught the attention of institutional investors who hold a sizeable 44% stake - Nov 4th, 2025 4:40 am
Traders Weigh US Government Shutdown, Fueling Premarket Losses for US Equity Futures - Oct 1st, 2025 7:10 am
FDA official’s comments spark Aurinia sell-off; Halozyme buys a biotech - Oct 1st, 2025 4:00 am
Enanta stock doubles despite RSV trial missing primary endpoint - Sep 30th, 2025 4:58 am
Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults - Sep 29th, 2025 11:28 am
Enanta Pharmaceuticals Says Zelicapavir Misses Phase 2 Primary Endpoint, But Shows RSV Improvement - Sep 29th, 2025 6:20 am